Quadratus Lumborum Block for Total Hip Arthroplasty

University of California, Los Angeles (UCLA)

Status and phase: Enrolling; Early Phase 1

Conditions: Pain, Postoperative

Treatments: Drug: Placebo Comparator; Drug: Active Comparator

Study type: Interventional

Funder types: Other

Identifiers

NCT05247255

21-001850

Details and patient eligibility

About

The quadratus lumborum (QL) block is a fascial plane block that has been described to provide analgesia from T7-L3 dermatomes. The investigators aim to evaluate the efficacy of QL blocks in patients undergoing primary total hip arthroplasty (THA).

Full description

Investigators will enroll subjects planned for primary THA and allocate them into receiving a QL block with either saline or ropivacaine. Primary outcome will be pain scores over the first 48 hours after surgery.

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult subjects undergoing elective primary total hip arthroplasty

Exclusion criteria

• patients age < 18,
• documented allergy to local anesthetic
• presence of peripheral neuropathy
• patients with current long term opioid use defined as receiving an opioid on most days in a 90 day period
• patients with a contraindication to spinal and regional anesthesia such as coagulopathy or infection at the site of the regional technique.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

80 participants in 2 patient groups, including a placebo group

Intervention Group

Active Comparator group

Description:

Quadratus lumborum nerve block with 0.25% ropivacaine

Treatment:

Drug: Active Comparator

Control Group

Placebo Comparator group

Description:

Quadratus lumborum nerve block with saline

Treatment:

Drug: Placebo Comparator